Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease
BACKGROUND: Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aβ oligomers selectively, was used to detect Aβ oligomers in the plasma of patients with AD and healthy control individuals.
METHODS: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aβ42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11C-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of Aβ oligomer levels by MDS and other conventional AD biomarkers (CSF Aβ42, pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker.
RESULTS: The plasma levels of Aβ oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aβ oligomers by MDS vs. CSF Aβ42, r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aβ oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aβ oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250).
CONCLUSIONS: Plasma levels of Aβ oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Alzheimer's research & therapy - 9(2017), 1 vom: 15. Dez., Seite 98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Min Jeong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.07.2018 Date Revised 09.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13195-017-0324-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279107307 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279107307 | ||
| 003 | DE-627 | ||
| 005 | 20231225022209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-017-0324-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0930.xml |
| 035 | |a (DE-627)NLM279107307 | ||
| 035 | |a (NLM)29246249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Min Jeong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2018 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aβ oligomers selectively, was used to detect Aβ oligomers in the plasma of patients with AD and healthy control individuals | ||
| 520 | |a METHODS: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aβ42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11C-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of Aβ oligomer levels by MDS and other conventional AD biomarkers (CSF Aβ42, pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker | ||
| 520 | |a RESULTS: The plasma levels of Aβ oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aβ oligomers by MDS vs. CSF Aβ42, r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aβ oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aβ oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250) | ||
| 520 | |a CONCLUSIONS: Plasma levels of Aβ oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Amyloid-β protein | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Oligomer | |
| 650 | 7 | |a 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Aniline Compounds |2 NLM | |
| 650 | 7 | |a Benzothiazoles |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a amyloid beta-protein (1-42) |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 700 | 1 | |a Yi, SangHak |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jee-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Park, So Young |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Jae-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, In Kook |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Byoung Sub |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Gwang Je |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ji Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Kuntaek |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Sung Min |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Young Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Youn, Young Chul |e verfasserin |4 aut | |
| 700 | 1 | |a An, Seong Soo A |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, SangYun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d 2009 |g 9(2017), 1 vom: 15. Dez., Seite 98 |w (DE-627)NLM190604069 |x 1758-9193 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2017 |g number:1 |g day:15 |g month:12 |g pages:98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13195-017-0324-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2017 |e 1 |b 15 |c 12 |h 98 | ||